Alaunos Therapeutics, Inc. — Director's Dealing 2021

Mar 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZIOPHARM ONCOLOGY INC (ZIOP)
CIK: 0001107421
Period of Report: 2021-03-04

Reporting Person: Hagen Heidi (Director, Interim CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Common Stock	A	90000	$0.00	Acquired	122119	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-04	Employee Stock Option (right to buy)	$4.31	A	675000	Acquired	2031-03-04	Common Stock (675000)	Direct

Footnotes

F1: The shares will fully vest on 3/4/2022.

F2: 1/12th of the shares underlying this option will vest in equal monthly installments commencing one month after 3/4/2021.